Sonoma Pharmaceuticals Future Growth

Future criteria checks 2/6

Sonoma Pharmaceuticals is forecast to grow earnings and revenue by 53.7% and 27.1% per annum respectively while EPS is expected to grow by 81.2% per annum.

Key information

53.7%

Earnings growth rate

81.2%

EPS growth rate

Pharmaceuticals earnings growth	23.6%
Revenue growth rate	27.1%
Future return on equity	n/a
Analyst coverage	Low
Last updated	15 Jul 2024

Recent future growth updates

Recent updates

Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower

Aug 27

The Market Lifts Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Shares 75% But It Can Do More

Jul 12

Investors Aren't Entirely Convinced By Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues

May 26

Earnings and Revenue Growth Forecasts

NasdaqCM:SNOA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2026	21	-2	N/A	1	2
3/31/2025	16	-3	N/A	-2	2
6/30/2024	13	-5	-3	-3	N/A
3/31/2024	13	-5	-2	-2	N/A
12/31/2023	12	-5	-5	-5	N/A
9/30/2023	12	-6	-4	-4	N/A
6/30/2023	13	-6	-5	-5	N/A
3/31/2023	13	-5	-6	-6	N/A
12/31/2022	13	-7	-5	-5	N/A
9/30/2022	13	-6	-5	-5	N/A
6/30/2022	13	-5	-5	-5	N/A
3/31/2022	13	-5	-4	-4	N/A
12/31/2021	12	-6	-4	-4	N/A
9/30/2021	15	-5	-3	-3	N/A
6/30/2021	17	-5	-2	-2	N/A
3/31/2021	19	-5	-4	-3	N/A
12/31/2020	21	-3	-6	-5	N/A
9/30/2020	20	-4	-7	-7	N/A
6/30/2020	19	-5	-8	-8	N/A
3/31/2020	18	-4	-5	-5	N/A
12/31/2019	18	-5	-4	-4	N/A
9/30/2019	19	-6	-5	-5	N/A
6/30/2019	19	-8	-8	-8	N/A
3/31/2019	19	-12	-12	-12	N/A
12/31/2018	18	-13	-12	-12	N/A
9/30/2018	18	-14	-12	-12	N/A
6/30/2018	17	-14	-11	-11	N/A
3/31/2018	17	-14	N/A	-12	N/A
12/31/2017	17	-12	N/A	-12	N/A
9/30/2017	16	-9	N/A	-11	N/A
6/30/2017	14	-9	N/A	-10	N/A
3/31/2017	13	-9	N/A	-8	N/A
12/31/2016	11	-9	N/A	-7	N/A
9/30/2016	10	-14	N/A	-8	N/A
6/30/2016	8	-16	N/A	-9	N/A
3/31/2016	9	-15	N/A	-9	N/A
12/31/2015	11	-13	N/A	-10	N/A
9/30/2015	12	-14	N/A	-8	N/A
6/30/2015	14	-10	N/A	-8	N/A
3/31/2015	14	-8	N/A	-7	N/A
12/31/2014	13	1	N/A	-6	N/A
9/30/2014	13	6	N/A	-5	N/A
6/30/2014	14	5	N/A	-5	N/A
3/31/2014	14	4	N/A	-5	N/A
12/31/2013	14	-6	N/A	-4	N/A
9/30/2013	14	-7	N/A	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNOA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNOA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNOA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SNOA's revenue (27.1% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: SNOA's revenue (27.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SNOA's Return on Equity is forecast to be high in 3 years time

Sonoma Pharmaceuticals Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

Recent updates

Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower

Sonoma Pharmaceuticals, Inc. and Its Partner, the MicroSafe Group DMCC, Announce That the Australian Therapeutic Goods Administration Approves Extended Claims for Nanocyn Disinfectant and Sanitizer

First quarter 2025 earnings: EPS and revenues miss analyst expectations

The Market Lifts Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Shares 75% But It Can Do More

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Aug 14, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Aren't Entirely Convinced By Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues

Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores

Nasdaq Grants Extension to Sonoma Pharmaceuticals to Regain Minimum Bid Price Requirement

Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.785679 million.

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use

Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.392077 million.

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference

Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

New minor risk - Share price stability

Sonoma Pharmaceuticals Receives Letter from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price for its Common Stock

No longer forecast to breakeven

New major risk - Share price stability

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.29 loss in 1Q 2023)

Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller

Full year 2023 earnings released: US$1.52 loss per share (vs US$1.92 loss in FY 2022)

Sonoma Pharmaceuticals, Inc. Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union

Third quarter 2023 earnings released: US$0.62 loss per share (vs US$0.31 loss in 3Q 2022)

Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas

Second quarter 2023 earnings released: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022)

Sonoma Pharmaceuticals, Inc. Launches Two New Dermatological Products

Sonoma Pharmaceuticals, Inc. Announces CFO Changes

Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99M

Sonoma Pharmaceuticals, Inc. Announces Resignation of Jerry Dvonch as Chief Financial Officer

Sonoma Pharmaceuticals, Inc. Announces Close of Office in Woodstock, Georgia Effective on or Before December 31, 2022

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

Sonoma Pharmaceuticals, Inc. and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S

Insufficient new directors

Sonoma Pharmaceuticals, Inc. Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2022 earnings released: US$0.033 loss per share (vs US$0.075 profit in 2Q 2021)

Insufficient new directors

Insufficient new directors

Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe

Does Sonoma Pharmaceuticals (NASDAQ:SNOA) Have A Healthy Balance Sheet?

Sonoma Pharmaceuticals Announces Expanded Dental Care Line with a New Product for Professional Care in the U.S. and a New Product for Professional and Consumer Care in Switzerland

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

New 90-day high: US$9.64

Sonoma Pharmaceuticals, Inc. and Microderm Technologies Ltd. Announce That Dermodacyn Disinfecting Solution Is Now Available in Hong Kong and Thailand

Sonoma Pharmaceuticals, Inc. Announces Partnership with Gabriel Science, LLC for Dental Markets

Sonoma Pharmaceuticals, Inc. and Crown Laboratories, Inc. Announce Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products

Sonoma Pharmaceuticals reports FQ2 results

Sonoma Pharmaceuticals, Inc. announced delayed 10-Q filing

Sonoma Pharmaceuticals and MicroSafe Group Announces that Health Canada Authorized Nanocyn® Disinfectant & Sanitizer to be Sold in Canada as a Hard-Surface Disinfectant under COVID-19 Interim Measure

Sonoma Pharmaceuticals, Inc. Plans to Relocate Remaining Manufacturing to Mexico

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies